[go: up one dir, main page]

EP1567648A1 - Vecteur d'expression, procedes pour realiser des produits geniques heterologues et procede de selection de cellules recombinantes hautement productives - Google Patents

Vecteur d'expression, procedes pour realiser des produits geniques heterologues et procede de selection de cellules recombinantes hautement productives

Info

Publication number
EP1567648A1
EP1567648A1 EP03767642A EP03767642A EP1567648A1 EP 1567648 A1 EP1567648 A1 EP 1567648A1 EP 03767642 A EP03767642 A EP 03767642A EP 03767642 A EP03767642 A EP 03767642A EP 1567648 A1 EP1567648 A1 EP 1567648A1
Authority
EP
European Patent Office
Prior art keywords
gene
protein
cells
expression
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03767642A
Other languages
German (de)
English (en)
Inventor
Barbara Enenkel
Jürgen FIEDER
Ralf Otto
Stefanos Grammatikos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1567648A1 publication Critical patent/EP1567648A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector

Definitions

  • Figure 8 shows the correlation between antibody productivity (mAb F19) and GFP fluorescence using the cell pool ZB1 as an example.
  • This cell pool was obtained from transfection with the vector combination pBIDG-F19HC and pBIN-F19LC (Fig.3).
  • the pool was subjected to a sequential GFP-based FACS sorting. After each sort, the concentration of the antibody F19 in the cell culture supernatant of the pool was determined by ELISA and the specific productivity per cell and day (pg / c * d) was calculated. Each data point represents the average of at least three cultivation passages. A total of six sorts were carried out.
  • Modified promoters which have a minimal sequence homology to the wild-type sequence SEQ ID NO: 1 of the hamster ubiquitin / S27a promoter of at least 80%, better at least 85%, preferably at least 90%, more preferably at least 95% and particularly preferred are particularly preferred have at least 97% and have a corresponding promoter activity in a comparative reporter gene assay.
  • nucleotide sequence or “nucleic acid sequence” denotes an oligonucleotide, nucleotides, polynucleotides and their fragments as well as DNA or RNA of genomic or synthetic origin, which are present as a single or double strand and can represent the coding or the non-coding strand of a gene.
  • Standard techniques such as, for example, site-specific mutagenesis or PCR-mediated mutagenesis (for example described in Sambrook et al., 1989 or Ausubel et al., 1994) can be used to modify nucleic acid sequences.
  • a person skilled in the art refers to a bivalent homodimeric scFv derivative as “diabody”.
  • the shortening of the peptide linker in the scFv molecule to 5-10 amino acids results in the formation of homodimers through the superposition of VH / VL chains.
  • the diabodies can also be stabilized by the introduction of disulfide bridges. Examples of diabodies can be found in the literature, for example in Perisic et al. (1994).
  • fragments which the person skilled in the art calls mini-antibodies and which have a bi-, tri- or tetravalent structure are also derivatives of scFv fragments.
  • the multimerization is achieved via di-, tri- or tetrameric “coiled coil” structures (Pack et al., 1993 and 1995; Lovejoy et al., 1993).
  • the fluorescence proteins used according to the invention also include natural or genetically engineered mutants and variants, their fragments, derivatives or e.g. Variants fused with other proteins or peptides.
  • the mutations introduced can change, for example, the excitation or emission spectrum, the formation of chromophores, the extinction coefficient or the stability of the protein. Codon optimization can also improve expression in mammalian cells or other species.
  • the fluorescent protein can also be used in fusion with a selection marker, preferably with an amplifiable selection marker such as, for example, dihydrofolate reductase (DHFR).
  • DHFR dihydrofolate reductase
  • enhancers are known to the person skilled in the art from various sources (and are stored in databases such as GenBank, for example SV40 enhancer, CMV enhancer, polyoma enhancer, adenovirus enhancer) and are available as independent elements or elements cloned within polynucleotide sequences (e.g. deposited at ATCC or from commercial and individual sources).
  • a variety of promoter sequences also include enhancer sequences, e.g. the commonly used CMV promoter.
  • the human CMV enhancer is one of the strongest enhancers identified to date.
  • An example of an inducible enhancer is the metallothionein enhancer, which can be stimulated by glucocorticoids or heavy metals.
  • inducible promoters the activity of the promoter can be reduced or enhanced in response to a signal.
  • An example of an inducible pro motor is the tetracycline (tet) promoter.
  • tet tetracycline
  • tetO tetracycline operator sequences
  • tTA tetracycline-regulated transactivator protein
  • jun, fos, metallothionine and heat shock promoters see also Sambrook et al., 1989; Gossen et al., 1994).
  • Table 1 below gives examples of further amplifiable selection marker genes which can be used according to the invention and the associated selection agents, which are described in an overview by Kaufman, Methods in Enzymology, 185: 537-566 (1990).
  • the concentration of MTX in the first amplification step is preferably at least 200 nM, in an even more preferred embodiment at least 500 nM and can be increased in steps up to 1 / M. In individual cases, concentrations of over 1 ⁇ M can also be used.
  • PCR polymerase chain reaction sICAM: soluble intracellular adhesion molecule
  • the therapeutic protein sICAM and GFP were expressed together by a bicistronic and the DHFR by a separate transcription unit. Two to three weeks after the first selection in HT-free CHO-S-SFMII medium, the 5% of the cells with the highest GFP fluorescence were sorted out. After approximately two weeks of cultivation, the 5% cells with the highest GFP fluorescence were again isolated. In total, this sequential sorting was carried out six times. A good correlation between sICAM productivity and GFP fluorescence was shown (Fig. 4). The FACS-based selection alone, without any MTX amplification step, quickly isolated cell pools with high specific productivities of up to 16 pg / cell / day (Fig. 5).

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un vecteur d'expression pour eucaryotes comportant un gène codant pour une protéine d'intérêt, en liaison fonctionnelle avec un promoteur hamster-ubiquitine/S27a et avec un gène codant pour une protéine fluorescente. Ce vecteur d'expression comprend de préférence également un gène marqueur de sélection amplifiable. La présente invention porte également sur des cellules hôtes transfectées par ce vecteur d'expression, de préférence des cellules de mammifères, sur des procédés pour réaliser des produits géniques hétérologues et sur un procédé pour sélectionner des cellules hautement productives.
EP03767642A 2002-11-29 2003-11-25 Vecteur d'expression, procedes pour realiser des produits geniques heterologues et procede de selection de cellules recombinantes hautement productives Withdrawn EP1567648A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10256083 2002-11-29
DE10256083A DE10256083A1 (de) 2002-11-29 2002-11-29 Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
PCT/EP2003/013225 WO2004050879A1 (fr) 2002-11-29 2003-11-25 Vecteur d'expression, procedes pour realiser des produits geniques heterologues et procede de selection de cellules recombinantes hautement productives

Publications (1)

Publication Number Publication Date
EP1567648A1 true EP1567648A1 (fr) 2005-08-31

Family

ID=32403676

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03767642A Withdrawn EP1567648A1 (fr) 2002-11-29 2003-11-25 Vecteur d'expression, procedes pour realiser des produits geniques heterologues et procede de selection de cellules recombinantes hautement productives

Country Status (12)

Country Link
EP (1) EP1567648A1 (fr)
JP (1) JP2006507829A (fr)
KR (1) KR100820035B1 (fr)
CN (1) CN1717486A (fr)
AR (1) AR042244A1 (fr)
AU (1) AU2003292102A1 (fr)
BR (1) BR0316510A (fr)
CA (1) CA2507714A1 (fr)
DE (1) DE10256083A1 (fr)
MX (1) MXPA05005482A (fr)
TW (1) TWI321152B (fr)
WO (1) WO2004050879A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124760A1 (en) * 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP3075858B1 (fr) * 2007-12-21 2020-01-29 Novartis Ag Vecteur d'expression de mammifères
US9534226B2 (en) * 2009-02-27 2017-01-03 Novartis Ag Expression vector system comprising two selection markers
KR101239495B1 (ko) * 2011-01-21 2013-03-05 경상대학교산학협력단 αΑ-크리스탈린 유전자를 발현하는 재조합 아데노바이러스 및 이를 이용한 망막혈관 질환의 유전자 치료
CN103562386A (zh) * 2011-05-25 2014-02-05 国立大学法人冈山大学 Reic表达腺病毒载体
FR2981946B1 (fr) * 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
PL3027646T3 (pl) 2013-07-31 2019-03-29 Novartis Ag Nowe wektory selekcyjne i sposoby selekcji eukariotycznych komórek gospodarza
CN104404072B (zh) * 2014-11-24 2018-04-27 浙江大学 用标记基因预测外源基因表达量及筛选转基因家蚕的方法
CN106442685B (zh) * 2016-10-25 2019-03-26 山东大学 一种快速低成本筛选蛋白质表达条件的方法
SG11202013191TA (en) * 2018-07-13 2021-01-28 Lonza Ag Methods for improving production of biological products by reducing the level of endogenous protein
CA3137457A1 (fr) * 2019-05-07 2020-11-12 Amgen Inc. Vecteurs et systemes d'expression pour produire des proteines recombinees

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
DE69435112D1 (de) * 1993-09-10 2008-08-21 Univ Columbia Verwendung von grünem fluoreszenzprotein
US5491084A (en) * 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
EP0961830A1 (fr) * 1997-01-29 1999-12-08 Neurosearch A/S VECTEURS D'EXPRESSION ET PROCEDES D'EXPRESSION $i(IN VIVO) DE POLYPEPTIDES THERAPEUTIQUES
JP2003504059A (ja) * 1999-07-12 2003-02-04 ジェネンテック・インコーポレーテッド 発現ベクターと方法
EP1258255A1 (fr) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugués d'un anticorps contre CD44 et d'un maytansinoide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004050879A1 *

Also Published As

Publication number Publication date
MXPA05005482A (es) 2005-07-25
TWI321152B (en) 2010-03-01
CN1717486A (zh) 2006-01-04
JP2006507829A (ja) 2006-03-09
AU2003292102A1 (en) 2004-06-23
KR20050085203A (ko) 2005-08-29
BR0316510A (pt) 2005-10-04
WO2004050879A1 (fr) 2004-06-17
TW200502388A (en) 2005-01-16
CA2507714A1 (fr) 2004-06-17
DE10256083A1 (de) 2004-08-12
AR042244A1 (es) 2005-06-15
KR100820035B1 (ko) 2008-04-10

Similar Documents

Publication Publication Date Title
EP1567652B1 (fr) Nouveaux genes de la neomycine phosphotransferase et procede pour selectionner des cellules recombinantes hautement productives
EP2049671B1 (fr) Éléments régulateurs d'acide nucléique
US8975391B2 (en) Regulatory elements
EP1658365B1 (fr) Procede de reclonage de cellules de production
US20090162900A1 (en) Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such of such products
WO2004050879A1 (fr) Vecteur d'expression, procedes pour realiser des produits geniques heterologues et procede de selection de cellules recombinantes hautement productives
DE10330686A1 (de) Neue Neomycin-Phosphotransferase-Gene und Verfahren zur Selektion von Hochproduzierenden rekombinanten Zellen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20050629

Extension state: LT

Payment date: 20050629

17Q First examination report despatched

Effective date: 20051213

17Q First examination report despatched

Effective date: 20051213

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: METHODS FOR THE PRODUCTION OF THE ANTIBODY MAK F19 COMPRISING THE SELECTION FOR HIGH-PRODUCING RECOMBINANT CELLS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110818